Featured
Zenbexus and the MRD Standard: How a 41-to-21 Ratio Rewrites the Myeloma Treatment Sequence
The FDA's August 13 accelerated approval of iberdomide (Zenbexus) with daratumumab and dexamethasone, on a 41 versus 21 percent MRD-negative response ...
Read Full Story →